调控UBR5的制剂在制备治疗色素性皮肤病药物的应用
By using AI drug screening technology to discover small molecule inhibitors EA and their analogues, and regulating UBR5 activity, new drugs for treating pigmented skin diseases have been developed, overcoming the limitations of existing treatment methods and achieving safe and effective melanin production inhibition and whitening effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- XIANGYA HOSPITAL CENT SOUTH UNIV
- Filing Date
- 2025-10-30
- Publication Date
- 2026-07-17
AI Technical Summary
Existing treatments for pigmented skin diseases have limited effectiveness, lacking safe and effective therapeutic targets and drugs. Traditional surgical and laser treatments also have risks and limitations.
AI-based virtual drug screening technology was used to discover small molecule inhibitors EA and their analogues, which inhibit UBR5 activity and regulate melanin production, leading to the development of new drugs for treating pigmented skin diseases. These drugs include sgRNA, UBR5 OE plasmids, and ellagic acid and its analogues such as punicin and corilagin, which are used to regulate melanin production.
It significantly inhibits melanin production, reduces melanin content and tyrosinase activity in melanocytes, demonstrating whitening efficacy and safety, and providing a potential treatment strategy for pigmented skin diseases.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3